MEDINDIA
English
हिन्दी
Español
français
中文
Email
Acebutolol
Regorafenib may increase the bradycardic activities of Acebutolol.
Acetyl Sulfisoxazole
The metabolism of Regorafenib can be decreased when combined with Acetyl sulfisoxazole.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Regorafenib.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Regorafenib.
Alprenolol
Regorafenib may increase the bradycardic activities of Alprenolol.
Amiodarone
The metabolism of Regorafenib can be decreased when combined with Amiodarone.
Amodiaquine
The serum concentration of Amodiaquine can be increased when it is combined with Regorafenib.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Regorafenib.
Apalutamide
The serum concentration of Regorafenib can be decreased when it is combined with Apalutamide.
Aprepitant
The serum concentration of Regorafenib can be increased when it is combined with Aprepitant.
Asenapine
Regorafenib may increase the bradycardic activities of Asenapine.
Asunaprevir
The serum concentration of Asunaprevir can be increased when it is combined with Regorafenib.
Atazanavir
The metabolism of Regorafenib can be decreased when combined with Atazanavir.
Atenolol
Regorafenib may increase the bradycardic activities of Atenolol.
Atomoxetine
The metabolism of Regorafenib can be decreased when combined with Atomoxetine.
Atorvastatin
The risk or severity of adverse effects can be increased when Regorafenib is combined with Atorvastatin.
Betaxolol
Regorafenib may increase the bradycardic activities of Betaxolol.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Regorafenib.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Regorafenib.
Bisoprolol
Regorafenib may increase the bradycardic activities of Bisoprolol.
Boceprevir
The metabolism of Regorafenib can be decreased when combined with Boceprevir.
Bopindolol
Regorafenib may increase the bradycardic activities of Bopindolol.
Bortezomib
The metabolism of Regorafenib can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Regorafenib can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Regorafenib can be decreased when it is combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Regorafenib.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Regorafenib.
Brentuximab Vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Regorafenib.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Regorafenib.
Bupranolol
Regorafenib may increase the bradycardic activities of Bupranolol.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Regorafenib.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Regorafenib.
Carbamazepine
The serum concentration of Regorafenib can be decreased when it is combined with Carbamazepine.
Carteolol
Regorafenib may increase the bradycardic activities of Carteolol.
Carvedilol
Regorafenib may increase the bradycardic activities of Carvedilol.
Celiprolol
Regorafenib may increase the bradycardic activities of Celiprolol.
Ceritinib
The serum concentration of Regorafenib can be increased when it is combined with Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Regorafenib.
Cilostazol
The serum concentration of Cilostazol can be increased when it is combined with Regorafenib.
Clarithromycin
The serum concentration of Regorafenib can be increased when it is combined with Clarithromycin.
Clemastine
The metabolism of Regorafenib can be decreased when combined with Clemastine.
Clotrimazole
The metabolism of Regorafenib can be decreased when combined with Clotrimazole.
Cobicistat
The metabolism of Regorafenib can be decreased when combined with Cobicistat.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Regorafenib.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Regorafenib.
Crizotinib
The metabolism of Regorafenib can be decreased when combined with Crizotinib.
Curcumin
The metabolism of Regorafenib can be decreased when combined with Curcumin.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Regorafenib.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Regorafenib.
Cyclosporine
The metabolism of Regorafenib can be decreased when combined with Cyclosporine.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Regorafenib.
Dabrafenib
The serum concentration of Regorafenib can be decreased when it is combined with Dabrafenib.
Darunavir
The metabolism of Regorafenib can be decreased when combined with Darunavir.
Dasatinib
The serum concentration of Regorafenib can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Regorafenib can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Regorafenib can be decreased when it is combined with Deferasirox.
Delavirdine
The metabolism of Regorafenib can be decreased when combined with Delavirdine.
Desipramine
Regorafenib may increase the bradycardic activities of Desipramine.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Regorafenib.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Regorafenib.
Digoxin
Regorafenib may increase the bradycardic activities of Digoxin.
Dihydroergocornine
The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Regorafenib.
Dihydroergocristine
The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Regorafenib.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Regorafenib.
Diltiazem
Regorafenib may increase the bradycardic activities of Diltiazem.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Regorafenib.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Regorafenib.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Regorafenib.
Doxorubicin Hydrochloride
The serum concentration of Doxorubicin can be increased when it is combined with Regorafenib.
Doxycycline
The metabolism of Regorafenib can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Regorafenib can be decreased when combined with Doxycycline.
Dronedarone
The metabolism of Regorafenib can be decreased when combined with Dronedarone.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Regorafenib.
Enzalutamide
The serum concentration of Regorafenib can be decreased when it is combined with Enzalutamide.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Regorafenib.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Regorafenib.
Erythromycin
The metabolism of Regorafenib can be decreased when combined with Erythromycin.
Esmolol
Regorafenib may increase the bradycardic activities of Esmolol.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Regorafenib.
Fluconazole
The metabolism of Regorafenib can be decreased when combined with Fluconazole.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Regorafenib.
Fluvoxamine
The metabolism of Regorafenib can be decreased when combined with Fluvoxamine.
Fosamprenavir
The metabolism of Regorafenib can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Regorafenib can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The serum concentration of Regorafenib can be decreased when it is combined with Fosphenytoin.
Fusidate
The serum concentration of Regorafenib can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Regorafenib can be increased when it is combined with Fusidic Acid.
Hypoxis hemerocallidea root extract
The serum concentration of Regorafenib can be decreased when it is combined with St. John's Wort.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Regorafenib.
Idelalisib
The metabolism of Regorafenib can be decreased when combined with Idelalisib.
Imatinib
The metabolism of Regorafenib can be decreased when combined with Imatinib.
Indinavir
The metabolism of Regorafenib can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Regorafenib can be decreased when combined with Indinavir.
Irinotecan
The serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Regorafenib.
Isavuconazole
The serum concentration of Regorafenib can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Regorafenib can be decreased when combined with Isavuconazonium.
Isradipine
The metabolism of Regorafenib can be decreased when combined with Isradipine.
Itraconazole
The serum concentration of Regorafenib can be increased when it is combined with Itraconazole.
Ivabradine
Regorafenib may increase the bradycardic activities of Ivabradine.
Ivacaftor
The serum concentration of Regorafenib can be increased when it is combined with Ivacaftor.
Ketoconazole
The serum concentration of Regorafenib can be increased when it is combined with Ketoconazole.
Labetalol
Regorafenib may increase the bradycardic activities of Labetalol.
Ledipasvir
The serum concentration of Ledipasvir can be increased when it is combined with Regorafenib.
Levobetaxolol
Regorafenib may increase the bradycardic activities of Levobetaxolol.
Levobunolol
Regorafenib may increase the bradycardic activities of Levobunolol.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Regorafenib.
Lopinavir
The metabolism of Regorafenib can be decreased when combined with Lopinavir.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Regorafenib.
Luliconazole
The serum concentration of Regorafenib can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Regorafenib can be decreased when it is combined with Lumacaftor.
Mepindolol
Regorafenib may increase the bradycardic activities of Mepindolol.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Regorafenib.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Regorafenib.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Regorafenib.
Metipranolol
Regorafenib may increase the bradycardic activities of Metipranolol.
Metoprolol
Regorafenib may increase the bradycardic activities of Metoprolol.
Mifepristone
The serum concentration of Regorafenib can be increased when it is combined with Mifepristone.
Mitotane
The serum concentration of Regorafenib can be decreased when it is combined with Mitotane.
Nadolol
Regorafenib may increase the bradycardic activities of Nadolol.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Regorafenib.
Nebivolol
Regorafenib may increase the bradycardic activities of Nebivolol.
Nefazodone
The metabolism of Regorafenib can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Regorafenib can be decreased when combined with Nelfinavir.
Netupitant
The serum concentration of Regorafenib can be increased when it is combined with Netupitant.
Nevirapine
The serum concentration of Regorafenib can be decreased when it is combined with Nevirapine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Regorafenib.
Nilotinib
The metabolism of Regorafenib can be decreased when combined with Nilotinib.
Nintedanib
The serum concentration of Nintedanib can be increased when it is combined with Regorafenib.
Olaparib
The metabolism of Regorafenib can be decreased when combined with Olaparib.
Osimertinib
The serum concentration of Regorafenib can be increased when it is combined with Osimertinib.
Ouabain
Ouabain may decrease the cardiotoxic activities of Regorafenib.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Regorafenib.
Oxprenolol
Regorafenib may increase the bradycardic activities of Oxprenolol.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Regorafenib.
Palbociclib
The serum concentration of Regorafenib can be increased when it is combined with Palbociclib.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Regorafenib.
Penbutolol
Regorafenib may increase the bradycardic activities of Penbutolol.
Pentobarbital
The serum concentration of Regorafenib can be decreased when it is combined with Pentobarbital.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Regorafenib.
Phenobarbital
The serum concentration of Regorafenib can be decreased when it is combined with Phenobarbital.
Phenytoin
The serum concentration of Regorafenib can be decreased when it is combined with Phenytoin.
Pindolol
Regorafenib may increase the bradycardic activities of Pindolol.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Regorafenib.
Posaconazole
The serum concentration of Regorafenib can be increased when it is combined with Posaconazole.
Practolol
Regorafenib may increase the bradycardic activities of Practolol.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Regorafenib.
Primidone
The serum concentration of Regorafenib can be decreased when it is combined with Primidone.
Propafenone
Regorafenib may increase the bradycardic activities of Propafenone.
Propranolol
Regorafenib may increase the bradycardic activities of Propranolol.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Regorafenib.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Regorafenib.
Rifabutin
The serum concentration of Regorafenib can be decreased when it is combined with Rifabutin.
Rifampin
The serum concentration of Regorafenib can be decreased when it is combined with Rifampicin.
Rifapentine
The serum concentration of Regorafenib can be decreased when it is combined with Rifapentine.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Regorafenib.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Regorafenib.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Regorafenib.
Rucaparib
The metabolism of Regorafenib can be decreased when combined with Rucaparib.
Saquinavir
The metabolism of Regorafenib can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Regorafenib can be decreased when combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Regorafenib can be decreased when used in combination with Sarilumab.
Sildenafil
The metabolism of Regorafenib can be decreased when combined with Sildenafil.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Regorafenib.
Siltuximab
The serum concentration of Regorafenib can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Regorafenib can be increased when it is combined with Simeprevir.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Regorafenib.
Sotalol
Regorafenib may increase the bradycardic activities of Sotalol.
ST. JOHN'S WORT EXTRACT
The serum concentration of Regorafenib can be decreased when it is combined with St. John's Wort.
Sulfisoxazole
The metabolism of Regorafenib can be decreased when combined with Sulfisoxazole.
Talinolol
Regorafenib may increase the bradycardic activities of Talinolol.
Telaprevir
The metabolism of Regorafenib can be decreased when combined with Telaprevir.
Telithromycin
The serum concentration of Regorafenib can be increased when it is combined with Telithromycin.
Terbutaline
Regorafenib may increase the bradycardic activities of Terbutaline.
Terbutaline Sulfate
Regorafenib may increase the bradycardic activities of Terbutaline.
Tertatolol
Regorafenib may increase the bradycardic activities of Tertatolol.
Ticlopidine
The metabolism of Regorafenib can be decreased when combined with Ticlopidine.
Timolol
Regorafenib may increase the bradycardic activities of Timolol.
Timolol Anhydrous
Regorafenib may increase the bradycardic activities of Timolol.
Tocilizumab
The serum concentration of Regorafenib can be decreased when it is combined with Tocilizumab.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Regorafenib.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Regorafenib.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Regorafenib.
Vemurafenib
The serum concentration of Regorafenib can be decreased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Regorafenib can be decreased when combined with Venlafaxine.
Verapamil
Regorafenib may increase the bradycardic activities of Verapamil.
Vincristine
The excretion of Vincristine can be decreased when combined with Regorafenib.
Voriconazole
The serum concentration of Regorafenib can be increased when it is combined with Voriconazole.
Warfarin
The risk or severity of adverse effects can be increased when Warfarin is combined with Regorafenib.
Ziprasidone
The metabolism of Regorafenib can be decreased when combined with Ziprasidone.
